调控溶酶体cathepsin B在DNA损伤剂依托泊苷抗前列腺癌中的作用及机制研究

基本信息
批准号:81803381
项目类别:青年科学基金项目
资助金额:21.00
负责人:王燕燕
学科分类:
依托单位:山东大学
批准年份:2018
结题年份:2021
起止时间:2019-01-01 - 2021-12-31
项目状态: 已结题
项目参与者:李平利,袁桂艳,陈绪旺,陈克广,郭楠,阚智慧,高云
关键词:
组织蛋白酶B依托泊苷前列腺癌侵袭转移DNA损伤
结项摘要

Transformation into hormone-independent prostate cancer and apoptosis resistance to chemotherapy are the major reasons of drug resistance, or metastasis in cancer therapy. Some studies suggest that the content of lysosome cathepsin B in prostate cancer is higher than that of normal tissue. Therefore, the regulation of cathepsin B is expected to be a new way to further improve the efficacy of drugs. The preliminary study found that etoposide induced prostate cancer cells apoptosis in vitro and in vivo, and caused cathepsin B abnormal transport and distribution. Based on this finding, the work will be carried out as follows. Through study on localization, expression and activity of lysosomal cathepsin B induced by etoposide in prostate cancer cells, we reveal the mechanism and signal transduction of cathepsin B activation, and elucidate the material basis of the compound. Based on etoposide activity evaluation in vitro and in vivo, we study the molecular mechanism of regulating cathepsin B expression and activity in prostate cancer cell apoptosis, DNA damage, invasion and metastasis. After etoposide combined with inhibitors, we determine cell survival rate to reveal the relationship between cathepsin B regulation and drug efficacy improvement. Based on the completion of this project, we may provide a new choice in prostate cancer treatment, supply a theoretieal basis for combination drug therapy and offer a new idea to improve chemotherapy of prostate cancer patients.

前列腺癌激素非依赖性转化、抵抗化疗药物诱导的凋亡是导致其耐药、转移的重要原因,有研究提示前列腺癌cathepsin B含量比正常组织高,故调控cathepsin B有望成为提高药物疗效的新途径。申请人前期发现,etoposide体内外诱导凋亡的同时导致前列腺癌cathepsin B异常转运和分布。本项目拟开展:研究etoposide作用于前列腺癌溶酶体cathepsin B的定位、表达和活性,揭示cathepsin B激活机制,阐明化合物作用的物质基础;在体内外活性评价基础上,研究调控cathepsin B表达和活性在etoposide作用于前列腺癌凋亡、DNA损伤、侵袭转移中的机制;通过etoposide联合应用抑制剂揭示调控cathepsin B与提高药物疗效之间的关系,为前列腺癌药物治疗提供新的选择,为联合用药提供理论基础,也为进一步提高前列腺癌化疗疗效提供新的思路。

项目摘要

化疗药etoposide通过诱导DNA损伤和肿瘤细胞凋亡广泛应用于治疗多种癌症。Cathepsin B是溶酶体中的一种组织蛋白酶,在恶性肿瘤细胞的增殖和侵袭转移中起着重要作用。最近研究表明cathepsin B在肿瘤细胞中参与一系列凋亡通路,本课题主要研究cathepsin B在etoposide抗肿瘤中的作用机制。结果显示,在前列腺癌细胞中,etoposide能够引起溶酶体稳定性降低,导致cathepsin B从溶酶体中释放出来,并且活性和表达均增加。为了进一步研究cathepsin B的激活和etoposide诱导的细胞死亡之间的关系,我们采用cathepsin B的抑制剂CA074Me、cathepsin B释放的促进剂,或者应用小干扰RNA敲除cathepsin B的表达、转染过表达载体增加cathepsin B的表达,观察调控cathepsin B对etoposide诱导的细胞死亡的影响,结果表明,etoposide在体内和体外均通过cathepsin B依赖的方式导致DNA损伤和细胞凋亡。另外,cathepsin B参与了etoposide引起DNA损伤的ATM‐Chk2和ATR‐Chk1通路。以上结果表明,cathepsin B在etoposide抗前列腺癌中起着关键作用。该项目的完成,为前列腺癌药物治疗提供新的选择,为联合用药提供理论基础,也为进一步提高前列腺癌化疗疗效提供新的思路。

项目成果
{{index+1}}

{{i.achievement_title}}

{{i.achievement_title}}

DOI:{{i.doi}}
发表时间:{{i.publish_year}}

暂无此项成果

数据更新时间:2023-05-31

其他相关文献

1

The Role of Osteokines in Sarcopenia: Therapeutic Directions and Application Prospects

The Role of Osteokines in Sarcopenia: Therapeutic Directions and Application Prospects

DOI:10.3389/fcell.2021.735374
发表时间:2021
2

转录组与代谢联合解析红花槭叶片中青素苷变化机制

转录组与代谢联合解析红花槭叶片中青素苷变化机制

DOI:
发表时间:
3

坚果破壳取仁与包装生产线控制系统设计

坚果破壳取仁与包装生产线控制系统设计

DOI:10.19554/j.cnki.1001-3563.2018.21.004
发表时间:2018
4

肉苁蓉种子质量评价及药材初加工研究

肉苁蓉种子质量评价及药材初加工研究

DOI:10.11842/wst.2017.02.019
发表时间:2017
5

Bousangine A, a novel C-17-nor aspidosperma-type monoterpenoid indole alkaloid from Bousigonia angustifolia

Bousangine A, a novel C-17-nor aspidosperma-type monoterpenoid indole alkaloid from Bousigonia angustifolia

DOI:10.1016/j.fitote.2020.104491
发表时间:2020

相似国自然基金

1

DNA聚合酶eta调控依托泊苷诱发损伤修复的分子机理与肿瘤耐药

批准号:31800684
批准年份:2018
负责人:马晓璐
学科分类:C0507
资助金额:25.00
项目类别:青年科学基金项目
2

裂殖酵母Snf2家族蛋白Rrp2在依托泊苷诱导的DNA损伤应答中的作用

批准号:31571290
批准年份:2015
负责人:杜立林
学科分类:C0602
资助金额:65.00
项目类别:面上项目
3

溶酶体半胱氨酸蛋白酶cathepsin B介导癌细胞凋亡机制研究

批准号:30771051
批准年份:2007
负责人:刘建平
学科分类:C0705
资助金额:27.00
项目类别:面上项目
4

槐糖脂的结构修饰及其联合依托泊苷对食管癌细胞增殖的影响和机制研究

批准号:31400049
批准年份:2014
负责人:马晓静
学科分类:C0102
资助金额:24.00
项目类别:青年科学基金项目